hznp-10q_20210630.htm
false
Q2
0001492426
00-0000000
--12-31
us-gaap:OtherAssetsNoncurrent
us-gaap:OtherAssetsNoncurrent
us-gaap:AccruedLiabilitiesCurrent
us-gaap:AccruedLiabilitiesCurrent
us-gaap:OtherLiabilitiesNoncurrent
us-gaap:OtherLiabilitiesNoncurrent
P3Y
P3Y
P3Y
2021-07-31
2023-08-31
2026-04-30
P4Y7M6D
P4Y5M19D
P4Y14D
0001492426
2021-01-01
2021-06-30
xbrli:shares
0001492426
2021-07-29
iso4217:USD
0001492426
2021-06-30
0001492426
2020-12-31
iso4217:USD
xbrli:shares
0001492426
2021-04-01
2021-06-30
0001492426
2020-04-01
2020-06-30
0001492426
2020-01-01
2020-06-30
0001492426
us-gaap:CommonStockMember
2020-12-31
0001492426
us-gaap:TreasuryStockMember
2020-12-31
0001492426
us-gaap:AdditionalPaidInCapitalMember
2020-12-31
0001492426
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2020-12-31
0001492426
us-gaap:RetainedEarningsMember
2020-12-31
0001492426
us-gaap:CommonStockMember
2021-01-01
2021-03-31
0001492426
us-gaap:AdditionalPaidInCapitalMember
2021-01-01
2021-03-31
0001492426
2021-01-01
2021-03-31
0001492426
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2021-01-01
2021-03-31
0001492426
us-gaap:RetainedEarningsMember
2021-01-01
2021-03-31
0001492426
us-gaap:CommonStockMember
2021-03-31
0001492426
us-gaap:TreasuryStockMember
2021-03-31
0001492426
us-gaap:AdditionalPaidInCapitalMember
2021-03-31
0001492426
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2021-03-31
0001492426
us-gaap:RetainedEarningsMember
2021-03-31
0001492426
2021-03-31
0001492426
us-gaap:CommonStockMember
2021-04-01
2021-06-30
0001492426
us-gaap:AdditionalPaidInCapitalMember
2021-04-01
2021-06-30
0001492426
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2021-04-01
2021-06-30
0001492426
us-gaap:RetainedEarningsMember
2021-04-01
2021-06-30
0001492426
us-gaap:CommonStockMember
2021-06-30
0001492426
us-gaap:TreasuryStockMember
2021-06-30
0001492426
us-gaap:AdditionalPaidInCapitalMember
2021-06-30
0001492426
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2021-06-30
0001492426
us-gaap:RetainedEarningsMember
2021-06-30
0001492426
us-gaap:CommonStockMember
2019-12-31
0001492426
us-gaap:TreasuryStockMember
2019-12-31
0001492426
us-gaap:AdditionalPaidInCapitalMember
2019-12-31
0001492426
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-12-31
0001492426
us-gaap:RetainedEarningsMember
2019-12-31
0001492426
2019-12-31
0001492426
us-gaap:CommonStockMember
2020-01-01
2020-03-31
0001492426
us-gaap:AdditionalPaidInCapitalMember
2020-01-01
2020-03-31
0001492426
2020-01-01
2020-03-31
0001492426
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2020-01-01
2020-03-31
0001492426
us-gaap:RetainedEarningsMember
2020-01-01
2020-03-31
0001492426
us-gaap:CommonStockMember
2020-03-31
0001492426
us-gaap:TreasuryStockMember
2020-03-31
0001492426
us-gaap:AdditionalPaidInCapitalMember
2020-03-31
0001492426
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2020-03-31
0001492426
us-gaap:RetainedEarningsMember
2020-03-31
0001492426
2020-03-31
0001492426
us-gaap:CommonStockMember
2020-04-01
2020-06-30
0001492426
us-gaap:AdditionalPaidInCapitalMember
2020-04-01
2020-06-30
0001492426
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2020-04-01
2020-06-30
0001492426
us-gaap:RetainedEarningsMember
2020-04-01
2020-06-30
0001492426
us-gaap:CommonStockMember
2020-06-30
0001492426
us-gaap:TreasuryStockMember
2020-06-30
0001492426
us-gaap:AdditionalPaidInCapitalMember
2020-06-30
0001492426
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2020-06-30
0001492426
us-gaap:RetainedEarningsMember
2020-06-30
0001492426
2020-06-30
0001492426
hznp:AccruedTradeDiscountsAndRebatesMember
2021-01-01
2021-06-30
0001492426
us-gaap:AllowanceForUncollectibleCustomersLiabilityForAcceptancesMember
2021-01-01
2021-06-30
0001492426
hznp:VielaBioMember
2021-03-15
2021-03-15
0001492426
hznp:VielaBioMember
us-gaap:CommonStockMember
2021-03-15
hznp:Segment
0001492426
us-gaap:StockCompensationPlanMember
2021-04-01
2021-06-30
0001492426
us-gaap:StockCompensationPlanMember
2021-01-01
2021-06-30
0001492426
us-gaap:StockCompensationPlanMember
2020-04-01
2020-06-30
0001492426
us-gaap:StockCompensationPlanMember
2020-01-01
2020-06-30
0001492426
hznp:ExchangeableSeniorNotesMember
2020-04-01
2020-06-30
0001492426
hznp:ExchangeableSeniorNotesMember
2020-01-01
2020-06-30
xbrli:pure
0001492426
hznp:ExchangeableSeniorNotesMember
2020-06-30
0001492426
hznp:VielaBioMember
2021-03-15
0001492426
hznp:VielaBioMember
2021-01-01
2021-06-30
0001492426
hznp:VielaBioMember
2021-06-30
0001492426
hznp:VielaBioMember
2021-04-01
2021-06-30
0001492426
hznp:VielaBioMember
hznp:BeforeMember
2021-06-30
0001492426
hznp:VielaBioMember
hznp:AdjustmentsMember
2021-06-30
0001492426
hznp:VielaBioMember
hznp:AfterMember
2021-06-30
0001492426
hznp:UPLIZNAMember
2021-03-31
0001492426
hznp:UPLIZNAMember
2021-06-30
0001492426
hznp:VielaBioMember
us-gaap:ResearchAndDevelopmentExpenseMember
2021-01-01
2021-06-30
0001492426
hznp:VielaBioMember
2020-01-01
2020-06-30
0001492426
us-gaap:AcquisitionRelatedCostsMember
hznp:VielaBioMember
2020-01-02
2020-01-02
0001492426
hznp:CurzionPharmaceuticalsIncMember
2021-06-30
0001492426
hznp:RAVICTIAndBUPHENYLMember
2020-12-31
0001492426
hznp:RAVICTIAndBUPHENYLMember
2020-01-01
2020-12-31
0001492426
hznp:RiverVisionDevelopmentCorpMember
2017-05-08
0001492426
hznp:RiverVisionDevelopmentCorpMember
2017-05-07
2017-05-08
0001492426
hznp:RiverVisionDevelopmentCorpMember
2021-06-30
0001492426
hznp:RiverVisionDevelopmentCorpMember
hznp:USFoodAndDrugAdministrationFDAApprovalMember
2021-06-30
0001492426
hznp:RiverVisionDevelopmentCorpMember
hznp:NetSalesThresholdsMember
hznp:TeprotumumabMember
2021-06-30
0001492426
hznp:RiverVisionDevelopmentCorpMember
2021-01-01
2021-06-30
0001492426
hznp:RiverVisionDevelopmentCorpMember
hznp:USFoodAndDrugAdministrationFDAApprovalMember
2020-03-31
iso4217:CHF
0001492426
hznp:RocheMember
2020-01-01
2020-03-31
iso4217:USD
iso4217:CHF
0001492426
hznp:RocheMember
2020-03-31
0001492426
2020-04-01
2020-04-30
0001492426
hznp:SROneAndLundbeckfondMember
2020-06-30
0001492426
hznp:TEPEZZAMember
2020-12-31
0001492426
hznp:TEPEZZAMember
hznp:RiverVisionDevelopmentCorpMember
2020-01-01
2020-12-31
0001492426
hznp:TEPEZZAMember
hznp:RocheMember
2020-01-01
2020-12-31
0001492426
hznp:TEPEZZADevelopedTechnologyMember
2021-01-01
2021-06-30
0001492426
hznp:TEPEZZADevelopedTechnologyMember
2020-12-31
0001492426
hznp:ArrowheadPharmaceuticalsMember
2021-07-01
2021-07-31
0001492426
hznp:ArrowheadPharmaceuticalsMember
2019-07-01
2019-07-31
0001492426
hznp:ArrowheadPharmaceuticalsMember
2021-04-01
2021-06-30
0001492426
hznp:ArrowheadPharmaceuticalsMember
2021-01-01
2021-06-30
0001492426
hznp:HalozymesMember
2020-01-01
2020-12-31
0001492426
hznp:HalozymesMember
2019-07-01
2019-07-31
0001492426
hznp:HalozymesMember
2021-04-01
2021-06-30
0001492426
hznp:HemoShearTherapeuticsLimitedLiabilityCompanyMember
2019-01-03
0001492426
hznp:HemoShearTherapeuticsLimitedLiabilityCompanyMember
2019-07-01
2019-07-31
0001492426
hznp:HemoShearTherapeuticsLimitedLiabilityCompanyMember
2020-07-01
2020-07-31
0001492426
hznp:HemoShearTherapeuticsLimitedLiabilityCompanyMember
2021-02-01
2021-02-28
0001492426
hznp:UPLIZNAMember
2021-04-01
2021-06-30
0001492426
hznp:UPLIZNAMember
2021-01-01
2021-06-30
0001492426
us-gaap:BuildingMember
2021-06-30
0001492426
us-gaap:BuildingMember
2020-12-31
0001492426
us-gaap:LandAndLandImprovementsMember
2021-06-30
0001492426
us-gaap:LandAndLandImprovementsMember
2020-12-31
0001492426
us-gaap:ConstructionInProgressMember
2021-06-30
0001492426
us-gaap:ConstructionInProgressMember
2020-12-31
0001492426
us-gaap:MachineryAndEquipmentMember
2021-06-30
0001492426
us-gaap:MachineryAndEquipmentMember
2020-12-31
0001492426
us-gaap:SoftwareAndSoftwareDevelopmentCostsMember
2021-06-30
0001492426
us-gaap:SoftwareAndSoftwareDevelopmentCostsMember
2020-12-31
0001492426
us-gaap:FurnitureAndFixturesMember
2021-06-30
0001492426
us-gaap:FurnitureAndFixturesMember
2020-12-31
0001492426
us-gaap:LeaseholdImprovementsMember
2021-06-30
0001492426
us-gaap:LeaseholdImprovementsMember
2020-12-31
0001492426
us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember
2021-06-30
0001492426
us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember
2020-12-31
0001492426
hznp:DeerfieldIllinoisMember
2020-02-01
2020-02-26
hznp:Building
0001492426
hznp:DeerfieldIllinoisMember
2020-02-26
utr:acre
utr:sqft
0001492426
hznp:OrphanMember
2020-12-31
0001492426
hznp:InflammationMember
2020-12-31
0001492426
hznp:OrphanMember
2021-01-01
2021-06-30
0001492426
hznp:OrphanMember
2021-06-30
0001492426
hznp:InflammationMember
2021-06-30
0001492426
hznp:VielaAcquisitionMember
2021-01-01
2021-03-31
0001492426
hznp:VielaAcquisitionMember
2021-04-01
2021-06-30
0001492426
us-gaap:DevelopedTechnologyRightsMember
hznp:UPLIZNAMember
2021-03-15
2021-03-15
0001492426
us-gaap:DevelopedTechnologyRightsMember
hznp:TEPEZZAMember
2020-01-01
2020-12-31
0001492426
us-gaap:DevelopedTechnologyRightsMember
2021-06-30
0001492426
us-gaap:InProcessResearchAndDevelopmentMember
2021-06-30
0001492426
us-gaap:CustomerRelationshipsMember
2021-06-30
0001492426
us-gaap:DevelopedTechnologyRightsMember
2020-12-31
0001492426
us-gaap:CustomerRelationshipsMember
2020-12-31
0001492426
us-gaap:InProcessResearchAndDevelopmentMember
hznp:VielaAcquisitionMember
2021-01-01
2021-06-30
0001492426
us-gaap:DevelopedTechnologyRightsMember
hznp:VielaAcquisitionMember
2021-01-01
2021-06-30
0001492426
hznp:VielaAcquisitionMember
2021-01-01
2021-06-30
0001492426
hznp:AccruedGovernmentRebatesAndChargeBacksMember
2021-06-30
0001492426
hznp:AccruedGovernmentRebatesAndChargeBacksMember
2020-12-31
0001492426
hznp:AccruedCoPayAndOtherPatientAssistanceMember
2021-06-30
0001492426
hznp:AccruedCoPayAndOtherPatientAssistanceMember
2020-12-31
0001492426
hznp:AccruedCommercialRebatesAndWholesalerFeesMember
2021-06-30
0001492426
hznp:AccruedCommercialRebatesAndWholesalerFeesMember
2020-12-31
0001492426
hznp:AccruedTradeDiscountsAndRebatesMember
2021-06-30
0001492426
hznp:AccruedTradeDiscountsAndRebatesMember
2020-12-31
0001492426
hznp:InvoicedWholesalerFeesAndCommercialRebatesCoPayAndOtherPatientAssistanceCostsAndGovernmentRebatesAndChargebacksInAccountsPayableMember
2021-06-30
0001492426
hznp:InvoicedWholesalerFeesAndCommercialRebatesCoPayAndOtherPatientAssistanceCostsAndGovernmentRebatesAndChargebacksInAccountsPayableMember
2020-12-31
0001492426
us-gaap:AllowanceForUncollectibleCustomersLiabilityForAcceptancesMember
2021-06-30
0001492426
us-gaap:AllowanceForUncollectibleCustomersLiabilityForAcceptancesMember
2020-12-31
0001492426
hznp:GovernmentRebatesAndChargeBacksMember
2020-12-31
0001492426
hznp:CoPayAndOtherPatientAssistanceMember
2020-12-31
0001492426
hznp:WholesalerFeesAndCommercialRebatesMember
2020-12-31
0001492426
hznp:GovernmentRebatesAndChargeBacksMember
2021-01-01
2021-06-30
0001492426
hznp:CoPayAndOtherPatientAssistanceMember
2021-01-01
2021-06-30
0001492426
hznp:WholesalerFeesAndCommercialRebatesMember
2021-01-01
2021-06-30
0001492426
hznp:GovernmentRebatesAndChargeBacksMember
hznp:VielaAcquisitionMember
2021-01-01
2021-06-30
0001492426
hznp:CoPayAndOtherPatientAssistanceMember
hznp:VielaAcquisitionMember
2021-01-01
2021-06-30
0001492426
hznp:WholesalerFeesAndCommercialRebatesMember
hznp:VielaAcquisitionMember
2021-01-01
2021-06-30
0001492426
us-gaap:AllowanceForUncollectibleCustomersLiabilityForAcceptancesMember
hznp:VielaAcquisitionMember
2021-01-01
2021-06-30
0001492426
hznp:GovernmentRebatesAndChargeBacksMember
2021-06-30
0001492426
hznp:CoPayAndOtherPatientAssistanceMember
2021-06-30
0001492426
hznp:WholesalerFeesAndCommercialRebatesMember
2021-06-30
0001492426
hznp:TEPEZZAMember
2021-04-01
2021-06-30
0001492426
hznp:TEPEZZAMember
2020-04-01
2020-06-30
0001492426
hznp:TEPEZZAMember
2021-01-01
2021-06-30
0001492426
hznp:TEPEZZAMember
2020-01-01
2020-06-30
0001492426
hznp:KRYSTEXXAMember
2021-04-01
2021-06-30
0001492426
hznp:KRYSTEXXAMember
2020-04-01
2020-06-30
0001492426
hznp:KRYSTEXXAMember
2021-01-01
2021-06-30
0001492426
hznp:KRYSTEXXAMember
2020-01-01
2020-06-30
0001492426
hznp:RAVICTIMember
2021-04-01
2021-06-30
0001492426
hznp:RAVICTIMember
2020-04-01
2020-06-30
0001492426
hznp:RAVICTIMember
2021-01-01
2021-06-30
0001492426
hznp:RAVICTIMember
2020-01-01
2020-06-30
0001492426
hznp:PROCYSBIMember
2021-04-01
2021-06-30
0001492426
hznp:PROCYSBIMember
2020-04-01
2020-06-30
0001492426
hznp:PROCYSBIMember
2021-01-01
2021-06-30
0001492426
hznp:PROCYSBIMember
2020-01-01
2020-06-30
0001492426
hznp:ActimmuneMember
2021-04-01
2021-06-30
0001492426
hznp:ActimmuneMember
2020-04-01
2020-06-30
0001492426
hznp:ActimmuneMember
2021-01-01
2021-06-30
0001492426
hznp:ActimmuneMember
2020-01-01
2020-06-30
0001492426
hznp:BUPHENYLMember
2021-04-01
2021-06-30
0001492426
hznp:BUPHENYLMember
2020-04-01
2020-06-30
0001492426
hznp:BUPHENYLMember
2021-01-01
2021-06-30
0001492426
hznp:BUPHENYLMember
2020-01-01
2020-06-30
0001492426
hznp:QUINSAIRMember
2021-04-01
2021-06-30
0001492426
hznp:QUINSAIRMember
2020-04-01
2020-06-30
0001492426
hznp:QUINSAIRMember
2021-01-01
2021-06-30
0001492426
hznp:QUINSAIRMember
2020-01-01
2020-06-30
0001492426
hznp:OrphanSegmentNetSalesMember
2021-04-01
2021-06-30
0001492426
hznp:OrphanSegmentNetSalesMember
2020-04-01
2020-06-30
0001492426
hznp:OrphanSegmentNetSalesMember
2021-01-01
2021-06-30
0001492426
hznp:OrphanSegmentNetSalesMember
2020-01-01
2020-06-30
0001492426
hznp:PENNSAIDTwoPercentMember
2021-04-01
2021-06-30
0001492426
hznp:PENNSAIDTwoPercentMember
2020-04-01
2020-06-30
0001492426
hznp:PENNSAIDTwoPercentMember
2021-01-01
2021-06-30
0001492426
hznp:PENNSAIDTwoPercentMember
2020-01-01
2020-06-30
0001492426
hznp:DUEXISProductMember
2021-04-01
2021-06-30
0001492426
hznp:DUEXISProductMember
2020-04-01
2020-06-30
0001492426
hznp:DUEXISProductMember
2021-01-01
2021-06-30
0001492426
hznp:DUEXISProductMember
2020-01-01
2020-06-30
0001492426
hznp:RAYOSMember
2021-04-01
2021-06-30
0001492426
hznp:RAYOSMember
2020-04-01
2020-06-30
0001492426
hznp:RAYOSMember
2021-01-01
2021-06-30
0001492426
hznp:RAYOSMember
2020-01-01
2020-06-30
0001492426
hznp:VimovoMember
2021-04-01
2021-06-30
0001492426
hznp:VimovoMember
2020-04-01
2020-06-30
0001492426
hznp:VimovoMember
2021-01-01
2021-06-30
0001492426
hznp:VimovoMember
2020-01-01
2020-06-30
0001492426
hznp:InflammationMember
2021-04-01
2021-06-30
0001492426
hznp:InflammationMember
2020-04-01
2020-06-30
0001492426
hznp:InflammationMember
2021-01-01
2021-06-30
0001492426
hznp:InflammationMember
2020-01-01
2020-06-30
0001492426
hznp:OrphanMember
2021-04-01
2021-06-30
0001492426
hznp:OrphanMember
2020-04-01
2020-06-30
0001492426
hznp:OrphanMember
2020-01-01
2020-06-30
0001492426
hznp:InflammationMember
2021-04-01
2021-06-30
0001492426
hznp:InflammationMember
2020-04-01
2020-06-30
0001492426
hznp:InflammationMember
2021-01-01
2021-06-30
0001492426
hznp:InflammationMember
2020-01-01
2020-06-30
0001492426
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
srt:MinimumMember
2021-01-01
2021-06-30
0001492426
hznp:CustomerAMember
2021-04-01
2021-06-30
0001492426
hznp:CustomerBMember
2021-04-01
2021-06-30
0001492426
hznp:CustomerCMember
2021-04-01
2021-06-30
0001492426
hznp:CustomerDMember
2021-04-01
2021-06-30
0001492426
hznp:OtherCustomersMember
2021-04-01
2021-06-30
0001492426
hznp:CustomerAMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2021-04-01
2021-06-30
0001492426
hznp:CustomerBMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2021-04-01
2021-06-30
0001492426
hznp:CustomerCMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2021-04-01
2021-06-30
0001492426
hznp:CustomerDMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2021-04-01
2021-06-30
0001492426
hznp:OtherCustomersMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2021-04-01
2021-06-30
0001492426
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2021-04-01
2021-06-30
0001492426
hznp:CustomerAMember
2020-04-01
2020-06-30
0001492426
hznp:CustomerBMember
2020-04-01
2020-06-30
0001492426
hznp:CustomerCMember
2020-04-01
2020-06-30
0001492426
hznp:CustomerDMember
2020-04-01
2020-06-30
0001492426
hznp:OtherCustomersMember
2020-04-01
2020-06-30
0001492426
hznp:CustomerAMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2020-04-01
2020-06-30
0001492426
hznp:CustomerBMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2020-04-01
2020-06-30
0001492426
hznp:CustomerCMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2020-04-01
2020-06-30
0001492426
hznp:CustomerDMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2020-04-01
2020-06-30
0001492426
hznp:OtherCustomersMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2020-04-01
2020-06-30
0001492426
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2020-04-01
2020-06-30
0001492426
hznp:CustomerAMember
2021-01-01
2021-06-30
0001492426
hznp:CustomerBMember
2021-01-01
2021-06-30
0001492426
hznp:CustomerCMember
2021-01-01
2021-06-30
0001492426
hznp:CustomerDMember
2021-01-01
2021-06-30
0001492426
hznp:OtherCustomersMember
2021-01-01
2021-06-30
0001492426
hznp:CustomerAMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2021-01-01
2021-06-30
0001492426
hznp:CustomerBMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2021-01-01
2021-06-30
0001492426
hznp:CustomerCMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2021-01-01
2021-06-30
0001492426
hznp:CustomerDMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2021-01-01
2021-06-30
0001492426
hznp:OtherCustomersMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2021-01-01
2021-06-30
0001492426
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2021-01-01
2021-06-30
0001492426
hznp:CustomerAMember
2020-01-01
2020-06-30
0001492426
hznp:CustomerBMember
2020-01-01
2020-06-30
0001492426
hznp:CustomerCMember
2020-01-01
2020-06-30
0001492426
hznp:CustomerDMember
2020-01-01
2020-06-30
0001492426
hznp:OtherCustomersMember
2020-01-01
2020-06-30
0001492426
hznp:CustomerAMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2020-01-01
2020-06-30
0001492426
hznp:CustomerBMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2020-01-01
2020-06-30
0001492426
hznp:CustomerCMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2020-01-01
2020-06-30
0001492426
hznp:CustomerDMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2020-01-01
2020-06-30
0001492426
hznp:OtherCustomersMember
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2020-01-01
2020-06-30
0001492426
us-gaap:CustomerConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2020-01-01
2020-06-30
0001492426
country:US
2021-04-01
2021-06-30
0001492426
us-gaap:NonUsMember
2021-04-01
2021-06-30
0001492426
country:US
us-gaap:GeographicConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2021-04-01
2021-06-30
0001492426
country:US
2020-04-01
2020-06-30
0001492426
us-gaap:NonUsMember
2020-04-01
2020-06-30
0001492426
country:US
us-gaap:GeographicConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2020-04-01
2020-06-30
0001492426
country:US
2021-01-01
2021-06-30
0001492426
us-gaap:NonUsMember
2021-01-01
2021-06-30
0001492426
country:US
us-gaap:GeographicConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2021-01-01
2021-06-30
0001492426
country:US
2020-01-01
2020-06-30
0001492426
us-gaap:NonUsMember
2020-01-01
2020-06-30
0001492426
country:US
us-gaap:GeographicConcentrationRiskMember
us-gaap:RevenueFromContractWithCustomerMember
2020-01-01
2020-06-30
0001492426
us-gaap:MoneyMarketFundsMember
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueMeasurementsRecurringMember
2021-06-30
0001492426
us-gaap:MoneyMarketFundsMember
us-gaap:FairValueMeasurementsRecurringMember
2021-06-30
0001492426
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:OtherCurrentAssetsMember
2021-06-30
0001492426
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:OtherCurrentAssetsMember
2021-06-30
0001492426
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueMeasurementsRecurringMember
2021-06-30
0001492426
us-gaap:FairValueMeasurementsRecurringMember
2021-06-30
0001492426
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:OtherNoncurrentLiabilitiesMember
2021-06-30
0001492426
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:OtherNoncurrentLiabilitiesMember
2021-06-30
0001492426
us-gaap:MoneyMarketFundsMember
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueMeasurementsRecurringMember
2020-12-31
0001492426
us-gaap:MoneyMarketFundsMember
us-gaap:FairValueMeasurementsRecurringMember
2020-12-31
0001492426
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:OtherCurrentAssetsMember
2020-12-31
0001492426
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:OtherCurrentAssetsMember
2020-12-31
0001492426
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueMeasurementsRecurringMember
2020-12-31
0001492426
us-gaap:FairValueMeasurementsRecurringMember
2020-12-31
0001492426
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:OtherNoncurrentLiabilitiesMember
2020-12-31
0001492426
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:OtherNoncurrentLiabilitiesMember
2020-12-31
0001492426
hznp:TermLoanFacilityDueTwentyTwentyEightMember
2021-06-30
0001492426
hznp:TermLoanFacilityDueTwentyTwentySixMember
2021-06-30
0001492426
hznp:TermLoanFacilityDueTwentyTwentySixMember
2020-12-31
0001492426
hznp:SeniorNotesDueTwentyTwentySevenMember
2021-06-30
0001492426
hznp:SeniorNotesDueTwentyTwentySevenMember
2020-12-31
0001492426
hznp:HorizonPharmaUSAIncMember
hznp:NewIncrementalRevolvingCommitmentsMember
2021-03-15
0001492426
hznp:HorizonPharmaUSAIncMember
hznp:MayTwoThousandNineteenRefinancingLoansMember
2021-03-15
2021-03-15
0001492426
hznp:HorizonPharmaUSAIncMember
hznp:NewIncrementalRevolvingCommitmentsMember
2019-03-11
0001492426
hznp:HorizonPharmaUSAIncMember
hznp:LetterOfCreditSubFacilityMember
2019-03-11
0001492426
hznp:HorizonPharmaUSAIncMember
hznp:NewIncrementalRevolvingCommitmentsMember
2019-03-11
2019-03-11
0001492426
hznp:RefinancingLoansMember
2019-12-18
0001492426
hznp:RefinancingLoansMember
2019-12-18
2019-12-18
0001492426
hznp:RefinancingLoansMember
us-gaap:LondonInterbankOfferedRateLIBORMember
2019-12-18
2019-12-18
0001492426
hznp:RefinancingLoansMember
us-gaap:ScenarioPlanMember
2019-12-18
2019-12-18
0001492426
hznp:RefinancingLoansMember
us-gaap:LondonInterbankOfferedRateLIBORMember
us-gaap:ScenarioPlanMember
2019-12-18
2019-12-18
0001492426
hznp:RefinancingLoansMember
srt:MinimumMember
2019-12-18
2019-12-18
0001492426
hznp:RefinancingLoansMember
srt:MaximumMember
2019-12-18
2019-12-18
0001492426
hznp:TwoThousandNineteenTermLoanFacilityMember
2019-12-18
0001492426
hznp:TwoThousandNineteenTermLoanFacilityMember
2019-12-18
2019-12-18
0001492426
hznp:TwoThousandNineteenTermLoanFacilityMember
us-gaap:BaseRateMember
2019-12-18
2019-12-18
0001492426
hznp:TwoThousandNineteenTermLoanFacilityMember
us-gaap:ScenarioPlanMember
2019-12-18
2019-12-18
0001492426
hznp:TwoThousandNineteenTermLoanFacilityMember
us-gaap:BaseRateMember
us-gaap:ScenarioPlanMember
2019-12-18
2019-12-18
0001492426
hznp:TwoThousandNineteenTermLoanFacilityMember
srt:MinimumMember
2019-12-18
2019-12-18
0001492426
hznp:TwoThousandNineteenTermLoanFacilityMember
srt:MaximumMember
2019-12-18
2019-12-18
0001492426
hznp:TwoThousandNineteenTermLoanFacilityMember
2021-01-01
2021-06-30
0001492426
us-gaap:RevolvingCreditFacilityMember
us-gaap:LondonInterbankOfferedRateLIBORMember
2019-12-18
2019-12-18
0001492426
us-gaap:RevolvingCreditFacilityMember
2019-12-18
0001492426
us-gaap:RevolvingCreditFacilityMember
us-gaap:BaseRateMember
2019-12-18
2019-12-18
0001492426
us-gaap:RevolvingCreditFacilityMember
us-gaap:LondonInterbankOfferedRateLIBORMember
us-gaap:ScenarioPlanMember
2019-12-18
2019-12-18
0001492426
us-gaap:RevolvingCreditFacilityMember
us-gaap:BaseRateMember
us-gaap:ScenarioPlanMember
2019-12-18
2019-12-18
0001492426
us-gaap:RevolvingCreditFacilityMember
2019-12-18
2019-12-18
0001492426
hznp:TwoThousandNineteenTermLoanFacilityMember
hznp:HorizonPharmaSubsidiariesMember
2019-12-18
2019-12-18
0001492426
hznp:TwoThousandNineteenTermLoanFacilityMember
srt:ScenarioForecastMember
2021-09-15
2021-09-15
0001492426
hznp:TwoThousandNineteenTermLoanFacilityMember
srt:ScenarioForecastMember
2021-09-15
0001492426
us-gaap:RevolvingCreditFacilityMember
2021-06-30
0001492426
hznp:IncrementalLoansMember
2021-06-30
0001492426
hznp:RefinancingLoansMember
2021-06-30
0001492426
hznp:HyperionTherapeuticsIncMember
hznp:IncrementalLoansMember
hznp:UnderwrittenPublicOfferingMember
2021-06-30
0001492426
hznp:HyperionTherapeuticsIncMember
hznp:RefinancingLoansMember
hznp:UnderwrittenPublicOfferingMember
2021-06-30
0001492426
hznp:HorizonPharmaUSAIncMember
hznp:TwentyTwentySevenSeniorNotesMember
2019-07-16
0001492426
hznp:TwentyTwentySevenSeniorNotesMember
2019-07-16
0001492426
2019-07-16
0001492426
hznp:TwentyTwentyThreeSeniorNotesMember
2019-07-16
0001492426
hznp:TwentyTwentyFourSeniorNotesMember
2019-07-16
0001492426
hznp:SeniorSecuredTermLoansMember
2019-07-16
0001492426
hznp:TwentyTwentySevenSeniorNotesMember
2020-01-01
2020-06-30
0001492426
hznp:TwentyTwentySevenSeniorNotesMember
hznp:HorizonPharmaUSAIncMember
2019-07-16
2019-07-16
0001492426
hznp:TwentyTwentySevenSeniorNotesMember
hznp:DebtInstrumentRedemptionUpToFortyPercentMember
2019-07-16
2019-07-16
0001492426
hznp:TwentyTwentySevenSeniorNotesMember
hznp:DebtInstrumentRedemptionSomeOrAllMember
2019-07-16
2019-07-16
0001492426
hznp:TwentyTwentySevenSeniorNotesMember
hznp:DebtInstrumentRedemptionInWholeButNotInPartMember
2019-07-16
2019-07-16
0001492426
hznp:TwentyTwentySevenSeniorNotesMember
srt:MaximumMember
hznp:DebtInstrumentRedemptionUpToFortyPercentMember
2019-07-16
2019-07-16
0001492426
hznp:TwentyTwentySevenSeniorNotesMember
hznp:HorizonPharmaUSAIncMember
2020-01-01
2020-06-30
0001492426
hznp:TwentyTwentySevenSeniorNotesMember
2021-06-30
0001492426
hznp:DublinOfficeStStephenSGreenMember
2021-06-30
0001492426
hznp:DublinOfficeConnaughtHouseMember
2021-06-30
0001492426
hznp:LakeForestOfficeMember
2021-06-30
0001492426
hznp:NovatoOfficeMember
2021-06-30
0001492426
hznp:SouthSanFranciscoOfficeMember
2021-06-30
0001492426
hznp:RockvilleMarylandOfficeMember
2021-06-30
0001492426
hznp:ChicagoOfficeMember
2021-06-30
0001492426
hznp:GaithersburgMarylandOfficeMember
2021-06-30
0001492426
hznp:WashingtonDCOfficeMember
2021-06-30
0001492426
hznp:MannheimOfficeMember
2021-06-30
0001492426
hznp:DublinOfficeStStephenSGreenMember
2021-01-01
2021-06-30
0001492426
hznp:DublinOfficeConnaughtHouseMember
2021-01-01
2021-06-30
0001492426
hznp:LakeForestOfficeMember
2021-01-01
2021-06-30
0001492426
hznp:NovatoOfficeMember
2021-01-01
2021-06-30
0001492426
hznp:SouthSanFranciscoOfficeMember
2021-01-01
2021-06-30
0001492426
hznp:RockvilleMarylandOfficeMember
srt:MinimumMember
2021-01-01
2021-06-30
0001492426
hznp:RockvilleMarylandOfficeMember
srt:MaximumMember
2021-01-01
2021-06-30
0001492426
hznp:ChicagoOfficeMember
2021-01-01
2021-06-30
0001492426
hznp:GaithersburgMarylandOfficeMember
2021-01-01
2021-06-30
0001492426
hznp:WashingtonDCOfficeMember
2021-01-01
2021-06-30
0001492426
hznp:MannheimOfficeMember
2021-01-01
2021-06-30
0001492426
hznp:DublinOfficeMember
2019-10-31
0001492426
hznp:DublinOfficeMember
2021-06-30
0001492426
hznp:DublinOfficeMember
2021-01-01
2021-06-30
iso4217:EUR
0001492426
hznp:AGCBiologicsASMember
hznp:TEPEZZADrugSubstanceMember
2021-01-01
2021-06-30
iso4217:USD
iso4217:EUR
0001492426
hznp:AGCBiologicsASMember
hznp:TEPEZZADrugSubstanceMember
2021-06-30
0001492426
hznp:CatalentIndianaLLCMember
hznp:TEPEZZADrugProductMember
2021-01-01
2021-06-30
0001492426
hznp:BioTechnologyGeneralIsraelLtdMember
srt:MinimumMember
hznp:KRYSTEXXAMember
2021-01-01
2021-06-30
0001492426
hznp:BioTechnologyGeneralIsraelLtdMember
hznp:KRYSTEXXAMember
2021-01-01
2021-06-30
0001492426
hznp:BioTechnologyGeneralIsraelLtdMember
hznp:KRYSTEXXAMember
2021-06-30
0001492426
hznp:BoehringerIngelheimMember
hznp:ActimmuneMember
2021-01-01
2021-06-30
0001492426
hznp:BoehringerIngelheimMember
hznp:ActimmuneMember
2021-06-30
0001492426
hznp:RavictiBuphenylProcysbiPennsaidTwoPercentDuexisRayosQuinsairAndUpliznaMember
2021-06-30
0001492426
hznp:RiverVisionDevelopmentCorpMember
hznp:FDAApprovalMember
2021-06-30
0001492426
hznp:RiverVisionDevelopmentCorpMember
hznp:FDAApprovalMember
2021-01-01
2021-06-30
0001492426
hznp:RiverVisionDevelopmentCorpMember
hznp:NetSalesThresholdsMember
hznp:TeprotumumabMember
hznp:ScenarioOneMember
2021-06-30
0001492426
hznp:RiverVisionDevelopmentCorpMember
hznp:NetSalesThresholdsMember
hznp:TeprotumumabMember
hznp:ScenarioTwoMember
2021-06-30
0001492426
hznp:RiverVisionDevelopmentCorpMember
hznp:NetSalesThresholdsMember
hznp:TeprotumumabMember
hznp:ScenarioThreeMember
2021-06-30
0001492426
hznp:RiverVisionDevelopmentCorpMember
hznp:SROneAndLundbeckfondMember
2020-04-01
2020-04-30
0001492426
hznp:RocheMember
2021-06-30
0001492426
hznp:TEPEZZAMember
hznp:RocheMember
2020-01-01
2020-03-31
0001492426
hznp:TEPEZZAMember
hznp:RocheMember
2021-06-30
0001492426
srt:MinimumMember
hznp:RocheMember
2021-01-01
2021-06-30
0001492426
srt:MaximumMember
hznp:RocheMember
2021-01-01
2021-06-30
0001492426
hznp:RocheMember
2021-01-01
2021-06-30
0001492426
srt:MaximumMember
hznp:LundquistInstituteMember
2021-01-01
2021-06-30
0001492426
hznp:BoehringerIngelheimMember
srt:MaximumMember
2021-01-01
2021-06-30
0001492426
hznp:AROXDHMember
2021-06-18
2021-06-18
0001492426
hznp:AROXDHMember
srt:MaximumMember
2021-06-18
2021-06-18
0001492426
hznp:TEPEZZAMember
2020-01-01
2020-12-31
0001492426
hznp:CurzionPharmaceuticalsIncMember
2020-04-01
2020-04-01
0001492426
hznp:CurzionPharmaceuticalsIncMember
2020-04-01
0001492426
us-gaap:OtherAssetsMember
2021-01-01
2021-06-30
0001492426
us-gaap:OtherIncomeMember
2021-01-01
2021-06-30
0001492426
hznp:TEPEZZAAndKRYSTEXXAMember
2021-01-01
2021-06-30
0001492426
hznp:TwentyTwentyEquityIncentivePlanMember
2021-02-17
2021-02-17
0001492426
hznp:TwoThousandTwentyEmployeeSharePurchasePlanMember
2021-06-30
0001492426
hznp:TwoThousandTwentyEquityIncentivePlanMember
2021-06-30
0001492426
hznp:TwoThousandFourteenNonEmployeeStockPurchasePlanMember
2021-06-30
0001492426
hznp:TwentyEighteenEquityIncentivePlanMember
2021-06-30
0001492426
2020-01-01
2020-12-31
0001492426
hznp:VielaAcquisitionMember
2021-03-15
0001492426
hznp:VielaAcquisitionMember
srt:MinimumMember
2021-03-15
2021-03-15
0001492426
hznp:VielaAcquisitionMember
srt:MaximumMember
2021-03-15
2021-03-15
0001492426
hznp:VielaAcquisitionMember
2021-03-15
2021-03-15
0001492426
us-gaap:RestrictedStockUnitsRSUMember
2020-12-31
0001492426
us-gaap:RestrictedStockUnitsRSUMember
2021-01-01
2021-06-30
0001492426
us-gaap:RestrictedStockUnitsRSUMember
2021-06-30
0001492426
us-gaap:PerformanceSharesMember
2020-12-31
0001492426
us-gaap:PerformanceSharesMember
2021-01-01
2021-06-30
0001492426
us-gaap:PerformanceSharesMember
2021-06-30
0001492426
us-gaap:PerformanceSharesMember
us-gaap:ShareBasedCompensationAwardTrancheTwoMember
2020-01-01
2020-12-31
0001492426
us-gaap:PerformanceSharesMember
hznp:TEPEZZAMember
2020-01-01
2020-12-31
0001492426
us-gaap:PerformanceSharesMember
hznp:KeyExecutiveMember
2018-01-04
2018-01-05
0001492426
us-gaap:PerformanceSharesMember
us-gaap:ShareBasedCompensationAwardTrancheOneMember
2021-01-01
2021-06-30
0001492426
us-gaap:PerformanceSharesMember
us-gaap:ShareBasedCompensationAwardTrancheTwoMember
2021-01-01
2021-06-30
0001492426
us-gaap:PerformanceSharesMember
us-gaap:ShareBasedCompensationAwardTrancheThreeMember
2021-01-01
2021-06-30
0001492426
us-gaap:PerformanceSharesMember
us-gaap:ShareBasedCompensationAwardTrancheOneMember
2020-01-01
2020-12-31
0001492426
us-gaap:PerformanceSharesMember
srt:MinimumMember
2021-01-01
2021-06-30
0001492426
us-gaap:PerformanceSharesMember
srt:MaximumMember
2021-01-01
2021-06-30
0001492426
hznp:TEPEZZAMember
us-gaap:PerformanceSharesMember
2021-06-30
0001492426
us-gaap:CostOfSalesMember
2021-01-01
2021-06-30
0001492426
us-gaap:CostOfSalesMember
2020-01-01
2020-06-30
0001492426
us-gaap:ResearchAndDevelopmentExpenseMember
2021-01-01
2021-06-30
0001492426
us-gaap:ResearchAndDevelopmentExpenseMember
2020-01-01
2020-06-30
0001492426
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2021-01-01
2021-06-30
0001492426
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2020-01-01
2020-06-30
0001492426
hznp:EirGenPharmaLimitedMember
us-gaap:SubsequentEventMember
2021-07-01
2021-07-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(MARK ONE)
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2021
OR
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number 001-35238
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
Ireland |
|
Not Applicable |
(State or other jurisdiction
of incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
|
|
|
Connaught House, 1st Floor
1 Burlington Road, Dublin 4, D04 C5Y6, Ireland |
|
Not Applicable |
(Address of principal executive offices) |
|
(Zip Code) |
011 353 1 772 2100
(Registrant’s telephone number, including area code)
Not applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class |
Trading Symbol |
Name of each exchange on which registered |
Ordinary shares, nominal value $0.0001 per share |
HZNP |
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of ‘‘large accelerated filer,’’ ‘‘accelerated filer,’’ ‘‘smaller reporting company,’’ and ‘‘emerging growth company’’ in Rule 12b–2 of the Exchange Act.
Large accelerated filer |
☒ |
Accelerated filer |
☐ |
|
|
|
|
Non-accelerated filer |
☐ |
Smaller reporting company |
☐ |
|
|
|
|
Emerging growth company |
☐ |
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Number of registrant’s ordinary shares, nominal value $0.0001, outstanding as of July 29, 2021: 225,893,375.
HORIZON THERAPEUTICS PLC
INDEX
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
HORIZON THERAPEUTICS PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except nominal value and share data)
|
As of |
|
As of |
|
|
June 30, |
|
December 31, |
|
|
2021 |
|
2020 |
|
ASSETS |
|
|
|
|
|
|
CURRENT ASSETS: |
|
|
|
|
|
|
Cash and cash equivalents |
$ |
812,319 |
|
$ |
2,079,906 |
|
Restricted cash |
|
3,839 |
|
|
3,573 |
|
Accounts receivable, net |
|
735,433 |
|
|
659,701 |
|
Inventories, net |
|
258,676 |
|
|
75,283 |
|
Prepaid expenses and other current assets |
|
365,113 |
|
|
251,945 |
|
Total current assets |
|
2,175,380 |
|
|
3,070,408 |
|
Property and equipment, net |
|
220,142 |
|
|
189,037 |
|
Developed technology and other intangible assets, net |
|
3,119,709 |
|
|
1,782,962 |
|
In-process research and development |
|
880,000 |
|
|
— |
|
Goodwill |
|
1,069,031 |
|
|
413,669 |
|
Deferred tax assets, net |
|
610,559 |
|
|
560,841 |
|
Other assets |
|
132,595 |
|
|
55,699 |
|
Total assets |
$ |
8,207,416 |
|
$ |
6,072,616 |
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
CURRENT LIABILITIES: |
|
|
|
|
|
|
Accounts payable |
$ |
51,947 |
|
$ |
37,710 |
|
Accrued expenses and other current liabilities |
|
478,499 |
|
|
485,567 |
|
Accrued trade discounts and rebates |
|
306,364 |
|
|
352,463 |
|
Long-term debt—current portion |
|
16,000 |
|
|
— |
|
Total current liabilities |
|
852,810 |
|
|
875,740 |
|
LONG-TERM LIABILITIES: |
|
|
|
|
|
|
Long-term debt, net |
|
2,560,444 |
|
|
1,003,379 |
|
Deferred tax liabilities, net |
|
549,078 |
|
|
66,474 |
|
Other long-term liabilities |
|
171,448 |
|
|
101,672 |
|
Total long-term liabilities |
|
3,280,970 |
|
|
1,171,525 |
|
COMMITMENTS AND CONTINGENCIES |
|
|
|
|
|
|
SHAREHOLDERS’ EQUITY: |
|
|
|
|
|
|
Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at June 30, 2021 and December 31, 2020; 226,099,787 and 221,721,674 shares issued at June 30, 2021 and December 31, 2020, respectively, and 225,715,421 and 221,337,308 shares outstanding at June 30, 2021 and December 31, 2020, respectively |
|
22 |
|
|
22 |
|
Treasury stock, 384,366 ordinary shares at June 30, 2021 and December 31, 2020 |
|
(4,585 |
) |
|
(4,585 |
) |
Additional paid-in capital |
|
4,260,337 |
|
|
4,245,945 |
|
Accumulated other comprehensive loss |
|
(1,018 |
) |
|
(145 |
) |
Accumulated deficit |
|
(181,120 |
) |
|
(215,886 |
) |
Total shareholders’ equity |
|
4,073,636 |
|
|
4,025,351 |
|
Total liabilities and shareholders' equity |
$ |
8,207,416 |
|
$ |
6,072,616 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
1
HORIZON THERAPEUTICS PLC
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)
(In thousands, except share and per share data)
|
For the Three Months Ended June 30, |
|
|
For the Six Months Ended June 30, |
|
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
|
Net sales |
$ |
832,548 |
|
|
$ |
462,779 |
|
|
$ |
1,174,954 |
|
|
$ |
818,688 |
|
|
Cost of goods sold |
|
200,995 |
|
|
|
121,515 |
|
|
|
301,363 |
|
|
|
218,931 |
|
|
Gross profit |
|
631,553 |
|
|
|
341,264 |
|
|
|
873,591 |
|
|
|
599,757 |
|
|
OPERATING EXPENSES: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
139,834 |
|
|
|
81,068 |
|
|
|
197,527 |
|
|
|
108,277 |
|
|
Selling, general and administrative |
|
355,204 |
|
|
|
222,332 |
|
|
|
687,196 |
|
|
|
470,107 |
|
|
Impairment of long-lived asset |
|
— |
|
|
|
— |
|
|
|
12,371 |
|
|
|
— |
|
|
Gain on sale of asset |
|
(2,000 |
) |
|
|
— |
|
|
|
(2,000 |
) |
|
|
— |
|
|
Total operating expenses |
|
493,038 |
|
|
|
303,400 |
|
|
|
895,094 |
|
|
|
578,384 |
|
|
Operating income (loss) |
|
138,515 |
|
|
|
37,864 |
|
|
|
(21,503 |
) |
|
|
21,373 |
|
|
OTHER EXPENSE, NET: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net |
|
(22,581 |
) |
|
|
(18,571 |
) |
|
|
(36,041 |
) |
|
|
(35,915 |
) |
|
Loss on debt extinguishment |
|
— |
|
|
|
(17,254 |
) |
|
|
— |
|
|
|
(17,254 |
) |
|
Foreign exchange (loss) gain |
|
(39 |
) |
|
|
283 |
|
|
|
(887 |
) |
|
|
1,059 |
|
|
Other (expense) income, net |
|
(262 |
) |
|
|
632 |
|
|
|
2,962 |
|
|
|
1,074 |
|
|
Total other expense, net |
|
(22,882 |
) |
|
|
(34,910 |
) |
|
|
(33,966 |
) |
|
|
(51,036 |
) |
|
Income (loss) before (benefit) expense for income taxes |
|
115,633 |
|
|
|
2,954 |
|
|
|
(55,469 |
) |
|
|
(29,663 |
) |
|
(Benefit) expense for income taxes |
|
(42,484 |
) |
|
|
82,964 |
|
|
|
(90,235 |
) |
|
|
63,938 |
|
|
Net income (loss) |
$ |
158,117 |
|
|
$ |
(80,010 |
) |
|
$ |
34,766 |
|
|
$ |
(93,601 |
) |
|
Net income (loss) per ordinary share—basic |
$ |
0.70 |
|
|
$ |
(0.42 |
) |
|
$ |
0.15 |
|
|
$ |
(0.49 |
) |
|
Weighted average ordinary shares outstanding—basic |
|
225,119,684 |
|
|
|
192,705,535 |
|
|
|
224,523,538 |
|
|
|
191,426,864 |
|
|
Net income (loss) per ordinary share—diluted |
$ |
0.67 |
|
|
$ |
(0.42 |
) |
|
$ |
0.15 |
|
|
$ |
(0.49 |
) |
|
Weighted average ordinary shares outstanding—diluted |
|
235,191,860 |
|
|
|
192,705,535 |
|
|
|
234,719,830 |
|
|
|
191,426,864 |
|
|
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustments |
$ |
235 |
|
|
$ |
344 |
|
|
$ |
(586 |
) |
|
$ |
19 |
|
|
Pension remeasurements |
|
— |
|
|
|
— |
|
|
|
(287 |
) |
|
|
— |
|
|
Other comprehensive income (loss) |
|
235 |
|
|
|
344 |
|
|
|
(873 |
) |
|
|
19 |
|
|
Comprehensive income (loss) |
$ |
158,352 |
|
|
$ |
(79,666 |
) |
|
$ |
33,893 |
|
|
$ |
(93,582 |
) |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
HORIZON THERAPEUTICS PLC
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(UNAUDITED)
(In thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
Accumulated Other |
|
|
|
|
|
|
Total |
|
|
|
Ordinary Shares |
|
|
Treasury Stock |
|
|
Paid-in |
|
|
Comprehensive |
|
|
Accumulated |
|
|
Shareholders’ |
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Loss |
|
|
Deficit |
|
|
Equity |
|
Balances at December 31, 2020 |
|
|
221,721,674 |
|
|
$ |
22 |
|
|
|
384,366 |
|
|
$ |
(4,585 |
) |
|
$ |
4,245,945 |
|
|
$ |
(145 |
) |
|
$ |
(215,886 |
) |
|
$ |
4,025,351 |
|
Issuance of ordinary shares in conjunction with the exercise of stock options
and the vesting of restricted stock and performance stock units |
|
|
3,305,947 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
19,843 |
|
|
|
— |
|
|
|
— |
|
|
|
19,843 |
|
Ordinary shares withheld for payment of employees’ withholding tax liability |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(128,261 |
) |
|
|
— |
|
|
|
— |
|
|
|
(128,261 |
) |
Share-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
62,296 |
|
|
|
— |
|
|
|
— |
|
|
|
62,296 |
|
Currency translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(821 |
) |
|
|
— |
|
|
|
(821 |
) |
Pension remeasurements |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(287 |
) |
|
|
— |
|
|
|
(287 |
) |
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(123,351 |
) |
|
|
(123,351 |
) |
Balances at March 31, 2021 |
|
|
225,027,621 |
|
|
$ |
22 |
|
|
|
384,366 |
|
|
$ |
(4,585 |
) |
|
$ |
4,199,823 |
|
|
$ |
(1,253 |
) |
|
$ |
(339,237 |
) |
|
$ |
3,854,770 |
|
Issuance of ordinary shares in conjunction with the exercise of stock options
and the vesting of restricted stock and performance stock units |
|
|
597,169 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
7,996 |
|
|
|
— |
|
|
|
— |
|
|
|
7,996 |
|
Issuance of ordinary shares in conjunction with Employee Share Purchase Plan |
|
|
474,997 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
11,482 |
|
|
|
— |
|
|
|
— |
|
|
|
11,482 |
|
Ordinary shares withheld for payment of employees’ withholding tax liability |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(13,388 |
) |
|
|
— |
|
|
|
— |
|
|
|
(13,388 |
) |
Share-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
54,424 |
|
|
|
— |
|
|
|
— |
|
|
|
54,424 |
|
Currency translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
235 |
|
|
|
— |
|
|
|
235 |
|
Net income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
158,117 |
|
|
|
158,117 |
|
Balances at June 30, 2021 |
|
|
226,099,787 |
|
|
$ |
22 |
|
|
|
384,366 |
|
|
$ |
(4,585 |
) |
|
$ |
4,260,337 |
|
|
$ |
(1,018 |
) |
|
$ |
(181,120 |
) |
|
$ |
4,073,636 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
Accumulated Other |
|
|
|
|
|
|
Total |
|
|
|
Ordinary Shares |
|
|
Treasury Stock |
|
|
Paid-in |
|
|
Comprehensive |
|
|
Accumulated |
|
|
Shareholders’ |
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Loss |
|
|
Deficit |
|
|
Equity |
|
Balances at December 31, 2019 |
|
|
188,402,040 |
|
|
$ |
19 |
|
|
|
384,366 |
|
|
$ |
(4,585 |
) |
|
$ |
2,797,602 |
|
|
$ |
(1,905 |
) |
|
$ |
(605,682 |
) |
|
$ |
2,185,449 |
|
Issuance of ordinary shares in conjunction with the exercise of stock options
and the vesting of restricted stock and performance stock units |
|
|
2,560,573 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
7,049 |
|
|
|
— |
|
|
|
— |
|
|
|
7,049 |
|
Ordinary shares withheld for payment of employees’ withholding tax liability |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(46,664 |
) |
|
|
— |
|
|
|
— |
|
|
|
(46,664 |
) |
Share-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
56,421 |
|
|
|
— |
|
|
|
— |
|
|
|
56,421 |
|
Currency translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(325 |
) |
|
|
— |
|
|
|
(325 |
) |
Net loss |
|
|
— |
|
|
|
— |
|